Is Pluri, Inc. overvalued or undervalued?

As of 13 May 2025, Pluri, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios indicate significant financial distress, with a Price to Book Value of -8.32 and an EV to EBITDA of -1.69, reflecting negative valuations. Additionally, the P/E ratio is not applicable due to the company being loss-making.
In comparison to its peers, Pluri, Inc. has a less favorable standing; for instance, Pieris Pharmaceuticals, Inc. has a P/E of -13.97 and an EV to EBITDA of -9.60, while OncoCyte Corp. shows a P/E of -3.98 and an EV to EBITDA of -2.86. These comparisons highlight that Pluri, Inc. is not only struggling but also ranks poorly among its peers. The company's stock has underperformed significantly over the long term, with a 5-year return of -93.18% compared to the S&P 500's 92.42%, further reinforcing the notion of overvaluation.